19 Grants
2024
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential
Chang, Kyeong-Ok⋅Groutas, William Constantine⋅Kim, Yunjeong and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 2R01AI130092-06), $699,892USD, 2024-07-19 -- 2029-05-31
2021
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2
CHANG, KYEONG-OK⋅Groutas, William C and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI161085-01), $774,037USD, 2021-08-06 -- 2026-07-31
 
Small Molecule Protease Inhibitors against MERS-CoV
CHANG, KYEONG-OK⋅Groutas, William C and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI130092-04), $730,761USD, 2018-05-15 -- 2023-04-30
2020
Small Molecule Protease Inhibitors against MERS-CoV
CHANG, KYEONG-OK⋅Groutas, William C and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI130092-03), $732,873USD, 2018-05-15 -- 2023-04-30
2019
Small Molecule Protease Inhibitors against MERS-CoV
CHANG, KYEONG-OK⋅Groutas, William C and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI130092-02), $734,924USD, 05/15/2018 -- 04/30/2023
2018
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics
BOWLIN, TERRY L⋅CHANG, KYEONG-OK⋅Groutas, William C and SAIF, LINDA J
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI109039-05), $734,295USD, 02/01/2014 -- 01/31/2019
 
Small Molecule Protease Inhibitors against MERS-CoV
CHANG, KYEONG-OK⋅Groutas, William C and Perlman, Stanley
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI130092-01A1), $775,916USD, 05/15/2018 -- 04/30/2023
2017
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics
BOWLIN, TERRY L⋅CHANG, KYEONG-OK⋅Groutas, William C and SAIF, LINDA J
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI109039-04), $734,295USD, 02/01/2014 -- 01/31/2019
2016
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics
BOWLIN, TERRY L⋅CHANG, KYEONG-OK⋅Groutas, William C and SAIF, LINDA J
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI109039-03), $734,295USD, 02/01/2014 -- 01/31/2019
2015
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics
BOWLIN, TERRY L⋅CHANG, KYEONG-OK⋅Groutas, William C and SAIF, LINDA J
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI109039-02), $734,295USD, 02/01/2014 -- 01/31/2019
2014
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics
BOWLIN, TERRY L⋅CHANG, KYEONG-OK⋅Groutas, William C and SAIF, LINDA J
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI109039-01), $784,022USD, 02/01/2014 -- 01/31/2019
2013
Development of Novel Therapeutic Agents for Norovirus Infection
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI081891-05), $895,635USD, 03/15/2009 -- 02/28/2015
2012
Development of Novel Therapeutic Agents for Norovirus Infection
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI081891-04), $952,801USD, 03/15/2009 -- 02/28/2014
2011
Development of Novel Therapeutic Agents for Norovirus Infection
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI081891-03), $1,005,959USD, 03/15/2009 -- 02/28/2014
2010
Development of Novel Therapeutic Agents for Norovirus Infection
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI081891-02), $1,027,980USD, 03/15/2009 -- 02/28/2014
2009
Development of Novel Therapeutic Agents for Norovirus Infection
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1U01AI081891-01), $1,017,777USD, 03/15/2009 -- 02/28/2014
 
REPLICATION OF NOROVIRUSES IN CELL CULTURE
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5P20RR016443-10), $253,524USD, 07/01/2009 -- 06/30/2010
2008
REPLICATION OF NOROVIRUSES IN CELL CULTURE
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5P20RR016443-09-6681), $242,808USD, 07/01/2008 -- 06/30/2009
2007
REPLICATION OF NOROVIRUSES IN CELL CULTURE
CHANG, KYEONG-OK
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5P20RR016443-08), $169,487USD, 07/01/2007 -- 06/30/2008